Thrombopoietin receptor agonists (TPO-RAs) are approved for immune thrombocytopenia (ITP), but their impact on health-related quality of life (HRQoL) remains poorly investigated in clinical practice. The gene discussed is MPL; the disease is autoimmune thrombocytopenic purpura.